Drug intelligence / Profile preview

fentanyl + gabapentin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Sublingual, Transmucosal, Buccal, Transdermal, Intranasal

Overview

A combination of fentanyl (an opioid analgesic) and gabapentin (an anticonvulsant). This combination has been identified as potentially dangerous due to increased risk of respiratory depression and opioid-related deaths. Fentanyl acts primarily through mu opioid receptor activation while gabapentin's mechanism is not fully understood but involves modulation of calcium channels and possibly GABA neurotransmission.

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)ABCB1 (P-glycoprotein)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on fentanyl + gabapentin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + gabapentin.

Explore the full profile